2026 Headache Medicine Specialist Salary Guide: Migraine Neurologist Compensation

Headache medicine specialists — neurologists with fellowship training and UCNS (United Council for Neurologic Subspecialties) board certification in Headache Medicine — provide subspecialty care for complex headache disorders including chronic migraine, cluster headache, new daily persistent headache, intracranial hypertension, cervicogenic headache, and post-concussive headache. The subspecialty uniquely combines high-volume outpatient cognitive neurology with a growing procedural revenue stream — botulinum toxin injection for chronic migraine (the highest-volume therapeutic botulinum toxin indication nationally) and CGRP monoclonal antibody prescribing. Total compensation in 2026 runs from $260,000 to $450,000, with the range driven by academic vs. community setting, botulinum toxin injection volume, and whether the specialist's practice includes interventional headache procedures (nerve blocks, sphenopalatine ganglion stimulation).

Salary overview by practice setting

• Academic neurology department (headache medicine division): $260,000–$380,000; NIH NINDS headache research funding; UCNS headache medicine fellowship training; AHS (American Headache Society) leadership; clinical trial infrastructure for CGRP antagonist and monoclonal antibody trials; PSLF-eligible; lowest absolute compensation but highest research and teaching infrastructure
• Comprehensive headache center (community health system): $300,000–$420,000; multidisciplinary headache program (neurologist + behavioral health + physical therapy + biofeedback); high-volume botulinum toxin injection clinic; wRVU-based incentive; infusion center for IV dihydroergotamine, magnesium, ketorolac, Depacon (valproate) for status migrainosus; strong referral from neurology and primary care
• Private neurology practice with headache focus: $340,000–$460,000; full professional fee retention; botulinum toxin buy-and-bill margin on Botox supplied directly; CGRP monoclonal antibody prescribing drives return visit volume; highest income ceiling at practices with efficient botulinum toxin injection protocols and large migraine patient panels
• Telehealth headache neurology: $270,000–$370,000; growing access-focused model; established outpatient migraine management and CGRP antibody prescribing translate well to telemedicine; telehealth headache practices reduce overhead; some practices see patients in-person for initial evaluation and botulinum toxin, and telemedicine for follow-up

Fellowship and certification

UCNS Headache Medicine board certification requires completion of 1 year of UCNS-accredited headache medicine fellowship following neurology residency, plus examination. Approximately 60–80 headache medicine fellows complete training annually — the smallest fellowship pipeline of any UCNS subspecialty, creating significant supply constraint relative to demand. Migraine affects approximately 39 million Americans (12% of the population), and less than 600 UCNS-certified headache medicine specialists practice in the US, creating a patient-to-specialist ratio that makes headache medicine one of the most access-constrained subspecialties in neurology.

Billing and wRVU

• New patient headache evaluation: CPT 99205 (high complexity); 4.11 wRVU; comprehensive headache history, neurological examination, MRI/CT review, ICHD-3 classification, treatment planning; headache specialist new patient visits are extensive (45–90 minutes); often includes discussion of multiple preventive options, CGRP mechanism explanation, and acute rescue plan
• Established headache follow-up: CPT 99214–99215; professional fee $180–$280; monthly or quarterly migraine management; headache diary review, CGRP antibody effectiveness assessment, side effect management, disability tracking (MIDAS, HIT-6 scores); large established patient panels of 300–600 active migraine patients drive steady E&M revenue
• Botulinum toxin injection for chronic migraine (OnabotulinumtoxinA, Botox): CPT 64615 (chemodenervation of face and head muscles, bilateral); professional fee $700–$1,400; PREEMPT protocol (155 units, 31 injection sites, across frontalis, corrugator, procerus, occipitalis, temporalis, cervical paraspinal, trapezius); FDA-approved for chronic migraine (≥15 headache days/month, of which ≥8 are migraine); every 12 weeks; insurance-covered under J0585 buy-and-bill mechanism when physician supplies the drug; most high-volume headache practices purchase onabotulinumtoxinA directly (wholesale ~$5.00–$5.50/unit; 155 units per PREEMPT session at wholesale ~$775–$850; Medicare allows ~$1,100–$1,400 for J0585 at 155 units); net drug margin $300–$600 per session; at 200 PREEMPT patients × 4 sessions/year = 800 sessions/year × $400 margin = $320,000 in annual botulinum toxin drug margin — the largest income differentiator in headache medicine practice
• Greater occipital nerve (GON) block: CPT 64405 (injection of anesthetic and/or steroid, greater occipital nerve); professional fee $200–$400; 1.6 wRVU; local anesthetic ± steroid injection at occipital nerve for acute migraine rescue, chronic daily headache, or cluster headache; often performed same-visit as evaluation; rapidly done in office; bilateral GON block generates CPT 64405 × 2 (with modifier)
• Sphenopalatine ganglion (SPG) block: CPT 64505 (injection, sphenopalatine ganglion); professional fee $300–$600; transnasal intranasal approach (Tx360 device); acute and preventive migraine management; some headache specialists offer SPG block for chronic migraine, cluster, and PTH (post-traumatic headache)
• IV infusion for status migrainosus: CPT 96365 (initial 31–60 min infusion) + 96366 (each additional hour); professional fee $200–$500; IV dihydroergotamine (DHE-45), ketorolac, valproate, magnesium, prochlorperazine; infusion center billing when headache practice has an attached infusion suite; recurring revenue for patients with frequent refractory migraine requiring IV rescue
• CGRP monoclonal antibody prescribing management: Erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), eptinezumab (Vyepti IV); prescription management, prior authorization support, and medication failure documentation; professional fee billed via E&M visit (not separate drug code for the SQ self-injectable agents); Vyepti IV infusion by RN generates CPT 96365 professional component for the supervising physician if in-practice infusion center
• Neuroimaging review and interpretation: CPT 70553 (MRI brain with contrast) interpretation if radiologist did not read; uncommon in outpatient setting but relevant when headache specialist reviews imaging from outside facilities; more commonly the specialist reviews imaging without a separate billing event

Geographic variation

• Major academic headache centers (Mayo Clinic Headache, Jefferson Headache Center, Harvard/BWH, Cleveland Clinic, UCSF): $270,000–$400,000; highest-complexity referrals; cluster headache, new daily persistent headache, rare secondary headaches; clinical trial infrastructure; UCNS fellowship programs
• Urban comprehensive headache centers (community health systems): $310,000–$430,000; high migraine patient volume; strong botulinum toxin clinic revenue; multidisciplinary program infrastructure; excellent income-to-lifestyle ratio
• Sun Belt and high-demand markets (FL, TX, AZ): $330,000–$460,000; large migraine patient population; limited headache specialist supply; community headache centers generate significant botulinum toxin volume; competitive recruiting as health systems invest in neurology subspecialty programs
• Private neurology practices with headache subspecialty: $360,000–$480,000; full botulinum toxin buy-and-bill margin retained; high procedural revenue ceiling; national headache societies list these positions frequently

What we see at Ava Health

Headache medicine specialists are one of the highest-demand neurological subspecialties in our recruiting database, disproportionate to their numbers. With fewer than 600 UCNS-certified headache specialists in the US and 39 million migraine sufferers, the supply-demand imbalance is severe. Physicians who complete headache medicine fellowship are actively recruited immediately upon graduation. The income appeal of high-volume botulinum toxin injection practice (the PREEMPT protocol buy-and-bill margin is one of the most physician-favorable drug economics in any specialty) makes private and community practice headache positions particularly attractive to recent fellowship graduates. The most common recruiter ask: a headache specialist willing to build a comprehensive headache center from the ground up — botulinum toxin clinic, infusion suite, behavioral health integration — at a community health system that currently sends its complex headache patients to a distant academic center.

Related: Neurologist Salary Guide, Movement Disorders Specialist Salary Guide, Pain Management Physician Salary Guide, Neurohospitalist Salary Guide.